Unlock the Future of Cell Analysis with Celledonia™

10 June 2024 -- Meet Celledonia, the new and revolutionary benchtop cell analyser that will inform and expedite your bioprocesses and turn your data into actionable insights.

TechBio company Cytomos (www.cytomos.com) today announces the launch of its much-anticipated flagship benchtop solution Celledonia, which uses the company’s patented AuraCyt platform.

Celledonia – a benchtop cell analyser – provides rapid, unbiased and intuitive cell-specific insights. This has the potential to revolutionise biotech, from development to manufacturing. It will reduce development and technology transfer timelines, costs, labour and time-to-market for modalities including monoclonal antibodies (mAbs), T cell immunotherapies and induced pluripotent stem cells (iPSCs). The new technology can help to:
• Predict cell health, type and functions for T-cell-based immunotherapy development
• Provide near-real time information about the state and age of cell populations
• Signal optimal time for harvesting
• Select high-producing, stable clones for CHO CLD of mAbs
• Inform pluripotent expansion and differentiation strategy for stem cells.

Insights such as these unlock exponential value for the bioprocess industry, enabling rapid decision making and live process control. Celledonia makes it possible to improve and streamline cell line development and bioproduction processes, while improving CGT process control should enable earlier prediction of product failure or success.

Celledonia leverages the power of Cytomos’ AuraCyt platform, which integrates a proprietary semiconductor chip with narrow-channel fluidics that focus cells (5-30 μm) close to the surface of the chip. As the cells pass through an electric field, the sensors provide a unique ‘fingerprint’ of the cell, analysing a range of cell features simultaneously. The resulting data represent intrinsic cellular properties in near-real-time, delivering label-free, consistent, accurate and reliable cell analytics.

Cytomos CEO David Rigterink commented: “Celledonia finally enables more timely, game-changing decisions via its patented real-time AuraCyt platform by agnostically translating complex cell data into actionable insights. That offers the potential to greatly accelerate and improve Cell Line Development, CAR T manufacturing efficacy and iPSC productivity. By harnessing the power of dielectric spectroscopy and microelectronics, we can improve the pace and accuracy of single cell analysis. The technology fits into an evolving landscape of next-generation therapies that are driving the need for radical advances in cell analytics.”

Celledonia is designed for ease-of-use, to allow users across R&D laboratories and manufacturing sites to generate consistent, reliable and informative cell analytics in near real-time. It overcomes the limitations of many conventional cell analytic technologies by removing many of the obstacles that prevent quick and unbiased decision making, such as operator bias, the need for labels, or the generation of indigestible data.

Dr Fernanda Masri, the company’s chief commercial and innovation officer, and former head of innovation manufacturing and collaborations at CGT Catapult explains: “There is no need for markers or cell preparation, yet a multitude of single-cell attributes can be detected without operator bias. Simply load your cells directly from culture onto the Celledonia instrument and run your samples to generate data that the software turns into useful insights in mere minutes, rather than taking hours, or up to days to get results.”

Celledonia could provide the answers you are looking for, to achieve near real-time, reliable and consistent single-cell analytics. Get in touch with the Cytomos team at www.cytomos.com/contact-cytomos to find out how Celledonia can help you.

About Cytomos
Cytomos is a dynamic company developing ground-breaking cell analysis systems that can be used alone or alongside conventional technologies such as flow cytometry. Its flagship instrument Celledonia leverages the power of the company’s AuraCyt platform to closely monitor a broad range of cell features simultaneously. It collects data on intrinsic cellular properties in near-real-time, delivering unbiased, consistent, accurate and reliable predictive analytics for biomanufacturing and other applications.

• Pioneering: AuraCyt accelerates biological drug discovery and development, and streamlines manufacturing, with near-real-time monitoring potential and better prospects for automation.
• Label-free: The technology harnesses the power of dielectric spectroscopy and microelectronics and characterises cells without the need for labels and directly in media.
• Unbiased: The technology addresses the analytical challenges of cell and gene therapy developers and monoclonal antibodies (mAbs), with fast and sensitive detection of single-cell attributes. The platform generates predictive analytics for consistent decision-making without operator bias.
• Uniquely scalable: AuraCyt is the only scalable technology that can measure cellular physiology, based on near-real-time intrinsic single-cell properties.
With huge potential for applications across a range of markets, Cytomos is continuing to engage with well-known force multipliers in the bioprocessing and CGT space, including bioprocessing solution market leaders and cutting-edge TechBio partners set to dominate the Advanced Therapy Medicinal Products (ATMPs).

Cytomos’ mission is to become the undisputed PAT partner for cell analytics. AuraCyt will accelerate biological drug discovery and development, and it will streamline manufacturing, with near-real-time monitoring and better prospects for automation.